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Perioperative antithrombotic therapy could play a role in preventing
thromboembolic complications (TEC) after kidney transplantation (KTx),
but little is known on postoperative bleeding risks. This retrospective anal-
ysis comprises 2000 single-organ KTx recipients transplanted between 2011
and 2016 in the two largest transplant centers of the Netherlands. TEC and
bleeding events were scored ≤7 days post-KTx. Primary analyses were for
associations of antithrombotic therapy with incidence of TEC and bleed-
ing. Secondary analyses were for associations of other potential risk factors.
Mean age was 55  14 years, 59% was male and 60% received a living
donor kidney. Twenty-one patients (1.1%) had a TEC. Multiple donor
arteries [OR 2.79 (1.15–6.79)] and obesity [OR 2.85 (1.19–6.82)] were
identified as potential risk factors for TEC. Bleeding occurred in 88
patients (4.4%) and incidence varied significantly between different
antithrombotic therapies (P = 0.006). Cardiovascular disease [OR 2.01
(1.18–3.42)], pre-emptive KTx [OR 2.23 (1.28–3.89)], postoperative hep-
arin infusion [OR 1.69 (1.00–2.85)], and vitamin K antagonists [OR 6.60
(2.95–14.77)] were associated with an increased bleeding risk. Intraopera-
tive heparin and antiplatelet therapy were not associated with increased
bleeding risk. These regimens appear to be safe for the possible prevention
of TEC without increasing the risk for bleeding after KTx.
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Introduction
Renal graft thrombosis (RGT) is a serious complication
after kidney transplantation (KTx) and a major risk
factor for impaired graft function and graft loss [1].
Although RGT is rare, varying from 0.5% to 8% [1–5],
it has high morbidity and mortality and accounts for
up to 45% of graft loss in the first post-transplantation
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phase [2,6]. Known risk factors for RGT are donor age
<6 or >60 years, recipient age <5 or >50 years, cold
ischemic time (CIT) >24 h, atherosclerosis in the exter-
nal iliac, common iliac or renal artery, right donor kid-
neys, prior peritoneal dialysis, diabetes mellitus,
previous thrombosis in the recipient, technical difficul-
ties and hemodynamic instability during transplantation
[7]. RGT, deep venous thrombosis (DVT), and pul-
monary embolisms (PE) are collectively known as
thromboembolic complications (TEC). Incidence of
TEC after KTx is reported to vary between 0.6% and
9.1% [8–11]. The wide ranges reported are because of
the differences in study populations, with highest inci-
dences found in pediatric KTx and lowest in studies
involving living donor KTx [1–5]. In the KTx popula-
tion, risk factors for DVT are age >40 years, diabetes
mellitus, previous DVT and simultaneous pancreas–kid-
ney transplantation [1,8,10,11]. Since more elderly
patients with higher comorbidity are being transplanted,
incidence of TEC is likely to increase [8,12]. In vascular
surgery, intraoperative administration of heparin is
common with the aim to avoid thrombus formation at
the anastomoses and clamp sites [13,14]. In KTx, no
consensus or protocol for antithrombotic prophylaxis
exists. A common argument is the general belief that
dialysis-dependent patients, in contrast to pre-emptive
patients, are at greater risk for bleeding because of
combined effects of uremia, residual effect of heparin
used during dialysis and continuous platelet activation,
and thus exhaustion, through contact with the dialysis
membrane [15]. However, recent insights show that
dialysis-dependent and pre-emptive patients have com-
parable hemostatic profiles preoperatively and are at
risk of both bleeding and thrombotic complications
[15–17]. Risk of thrombosis should always be carefully
weighed against risk of bleeding, but evidence suggests
that the benefits of antithrombotic prophylaxis to pre-
vent postoperative thrombosis outweigh the risks of
bleeding in procedures such as KTx [18]. The aim of
this study was to assess early TEC and bleeding after




This retrospective cohort analysis comprises all adult
KTx recipients in two large tertiary university based
hospitals in the Netherlands, the University Medical
Center Groningen (UMCG) and the Erasmus Medical
Center in Rotterdam (EMC), transplanted between 2011
and 2016. Exclusion criteria for this study were com-
bined transplantations (36 patients), lack of data on
antithrombotic therapy (eight patients), or inaccessible
hospital records (13 patients). A total cohort of 2000
patients were further analyzed.
Patient charts were screened using the electronic hos-
pital registries for baseline characteristics, surgical
details, postoperative complications, patient and graft
outcome and preoperative antithrombotic prophylaxis
(Tables 1 and 2). Included were the following agents
with their Anatomical Therapeutic Chemical (ATC)
classification code: vitamin K antagonists (VKA; phen-
procoumon B01AA04 and acenocoumarol B01AA07),
low-molecular-weight heparin (LMWH; dalteparin
B01AB04 and nadroparin B01AB06), platelet function
inhibitors (clopidogrel B01AC04, aspirin B01AC06,
dipyridamole B01AC07, carbasalate calcium B01AC08,
prasugrel B01AC22 and ticagrelor B01AC24), novel oral
anticoagulants (NOACs; dabigatran B01AE07, rivaroxa-
ban B01AF01, apixaban B01AF02 and edoxaban
B01AF03) and intraoperative unfractionated heparin
(UFH) B01AB01.
For this study, the Medical Ethics Committee (MEC)
of the UMCG granted dispensation from the Medical
Research Involving Human Subjects Act (WMO) obliga-
tion (registration no. MEC2016.601) and this dispensa-
tion was submitted to and approved by the MEC of the
EMC. Patient data were processed and stored according
to the declaration of Helsinki – Ethical principles for
medical research involving human subjects. The clinical
and research activities are consistent with the Principles
of the Declaration of Istanbul as outlined in the “Decla-
ration of Istanbul on Organ Trafficking and Transplant
Tourism.”
Outcome measures
Primary outcome measures were associations of
antithrombotic therapy with incidence of TEC and
bleeding. Secondary analyses were for associations of
other potential risk factors.
Surgical procedure and center-based
immunosuppressive and antithrombotic protocol
Kidney transplantation was performed with either a liv-
ing or deceased donor kidney (donation after brain
death (DBD) or circulatory death (DCD)). According
to the protocol within EuroTransplant, DBD donors
received 20 000 IU of heparin prior to systemic
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Table 1. Incidence of postoperative TEC and baseline characteristics.
Baseline characteristics of KTx patients
Cases
P-valueCharacteristics No TEC TEC ≤7 days
N 1979 21
Gender
Male (%) 1198 10 0.23
Age in years





CAPD 330 5 0.32
Dialysis duration months 22  27 18  19 0.51
Ethnicity
Non-Caucasian 264 1 0.50
ASA score 3 (3–3) 3 (3–3) 0.51
BMI in kg/m2 ≥30 412 9 0.01
Baseline eGFR ≥10 604 6 0.83
CCI score 4 (3–6) 4 (3–6) 0.94
Co-morbidities
Diabetes 400 5 0.60
SLE 26 1 0.25
Cardiovascular disease 465 4 0.80
Peripheral vascular disease 162 1 0.99
Hypertension 1171 11 0.70
DVT in medical history 71 1 0.77
Coagulation disorders 19 0 0.99
Bleeding disorders 6 0 0.80
Smoking at time of KTx 385 2 0.40
Diabetic nephropathy 269 4 0.47
N arteries >1 354 8 0.04
N veins >1 54 1 0.45
Blood loss (ml) ≥500 320 6 0.15
Intraoperative diuresis
No 389 10 0.004
Donor type
Living donor 1193 10 0.24
DBD 381 6 0.70
DCD 403 5
Donor age (years) ≥60 693 11 0.10
Donor gender
Male (%) 962 10 0.92
Right kidney 695 9 0.25
Ischemic times in min.
1st WIT 5.7  8.5 5.6  5.7 0.71
CIT >24 h 14 1 0.03
2nd WIT 30.8  13.6 36.3  19.6 0.14
Preoperative Hb 7.4  1.0 7.2  1.1 0.23
Preoperative platelets 228  85 213  42 0.42
Antithrombotic therapy
None 1344 15 0.73
Continued VKA* 52 1 0.40
APT† 388 2 0.56
Intraoperative UFH 193 2 0.71
APT + intraoperative UFH 28 1 0.27
Postoperative heparin infusion 632 5 0.43
Transplant International 2018; 3
ª 2018 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT
Antithrombotic therapy in kidney transplantation
perfusion and flushout. DCD and living donors do not
receive any form of anticoagulation. After procurement,
kidneys were flushed and perfused with cold University
of Wisconsin solution (ViaSpan; DuPont, Wilmington,
NC, USA; Belzer UW; Bridge to life, Columbia, SC,
USA) and placed in either cold storage or using
hypothermic machine perfusion (national protocol for
all deceased donor kidneys since January 2016). No
heparin was added to the perfusates (cold storage or
machine perfusion). No subcutaneous heparin was
given to recipients intraoperatively. KTx was performed
according to local protocol and published before
[19,20]. Multiple artery reconstruction was performed
in either an end-to-end or end-to-side fashion in both
centers. In some deceased donors, attachment to the
aortic patch was possible and thus reconstruction was
not needed and sometimes the second artery was too
small, so it was sacrificed. At the UMCG, patients trans-
planted pre-emptively received 5000 IU UFH intra-
venously before clamping of the iliac vessels. In the
UMCG, Mannitol is given prior to reperfusion. In both
centers, no additional diuretics are administered. Intra-
operative diuresis was defined as visible urine coming
from the ureter before ureter-bladder anastomosis or
through the urinary catheter in case of absent diuresis
prior to surgery. All patients received induction therapy
with basiliximab, or occasionally anti-thymocyte globu-
lin, with exception of recipients with human leukocyte
antigen (HLA) mismatch of 000. Maintenance immuno-
suppression consisted of prednisolone, mycophenolic
acid, and tacrolimus. Between 2011 and 2013, patients
at the EMC were treated with 12 000 IU/24 h of con-
tinuous UFH (without sequential APTT measurements)
for 5 days after transplantation, starting 6 h postopera-
tively. In 2013, this protocol was changed and thereafter
only recipients of a kidney with reconstruction of multi-
ple arteries were treated with 12 000 IU/24 h of contin-
uous UFH for 5 days. All patients who did not receive
postoperative heparin infusion were given a prophylac-
tic dose of 2850 IU LMWH s.c. as part of hospital pro-
tocol for immobilized patients, starting 6 h
postoperatively. Three patients with history of heparin-
induced thrombocytopenia were excluded from this
protocol and some patients received therapeutic doses
of LMWH, which was adjusted according to renal
function.
Antithrombotic strategies
Antithrombotic therapy was divided into five groups:
none (control group, CG; n = 1333), intraoperative UFH
(UFH; n = 195), continued use of VKA (n = 53), contin-
ued use of antiplatelet therapy (APT; n = 390), and com-
bined continued use of APT and UFH (APT + UFH;
n = 29). Patients receiving dual APT (n = 9) were com-
bined with patients receiving single APT and analyzed as
one group. None of the patients used a NOAC at time of
surgery. Continued use of VKA was defined as a preoper-
ative INR > 1.5, which was not corrected and last admin-
istration was given at day of transplantation. Patients of
whom VKA therapy was bridged with heparin were
included in the VKA group (n = 25). VKA in the 18
patients with a living donor were ceased 3–5 days prior
to transplantation and bridged with heparin. The seven
patients with a deceased donor were first corrected for
INR by Vitamin K/phytomenadione or prothrombin
complex concentrate after admission to the hospital and
then bridged with heparin. Twenty-nine patients of CG-
group had a pre-transplant anticoagulation regime, but
were adequately and timely corrected for INR prior to
Table 1. Continued.
Baseline characteristics of KTx patients
Cases
P-valueCharacteristics No TEC TEC ≤7 days
AB0 – blood group Incompatible 72 2 0.19
DGF 453 2 0.44
Shown are baseline characteristics in n (%). Ordinal data are given as median with IQR. Continuous data as mean  SD.
N, number in group; CAPD, continuous ambulatory peritoneal dialysis; ASA, American society for anaesthesiologists; BMI, body
mass index; eGFR, estimated glomerular filtration rate; CCI, Charlson Comorbidity Index; SLE, systemic lupus erythematosus;
DVT, deep venous thrombosis; DBD, donation after brain death; DCD, donation after circulatory death; WIT, warm ischemic
time; CIT, cold ischemic time; VKA, Vitamin K antagonists; APT, antiplatelet therapy; UFH, unfractionated heparin.
*Administration of VKA on day of transplantation was continued and INR not corrected.
†Administration of APT was continued at the day of transplantation. Second WIT was defined as the time from cold storage
to recirculation (anastomosis time). CCI, which predicts the 1 year mortality for a patient, was scored for all recipients [34].
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Table 2. Incidence of postoperative bleeding and baseline characteristics.
Baseline characteristics of KTx patients
Cases
P-valueCharacteristics No bleeding Bleeding ≤7 days
n 1912 88
Gender (%)
Male 1157 51 0.63
Age in years
≥50 1255 61 0.48
Pre-emptive KTx 581 37 0.02
Dialysis-dependent KTx
Hemodialysis 1006 40
CAPD 324 11 0.64
Dialysis duration months 22  27 19  24 0.32
Ethnicity
Non-Caucasian 246 19 0.02
ASA score 3 (3–3) 3 (3–3) 0.06
BMI in kg/m2 ≥30 410 11 0.04
Baseline eGFR ≥10 574 36 0.03
CCI score 4 (3–6) 5 (3–6) 0.02
Co-morbidities
Diabetes 384 21 0.39
SLE 27 0 0.26
Cardiovascular disease 433 36 <0.001
Peripheral vascular disease 152 11 0.13
Hypertension 1129 53 0.82
DVT in medical history 68 4 0.56
Coagulation disorders 19 0 0.35
Bleeding disorders 6 0 1.00
Smoking at time of KTx 378 9 0.02
Diabetes nephropathy 256 17 0.11
N arteries >1 342 20 0.24
N veins >1 55 0 0.11
Blood loss (ml) ≥500 304 22 0.12
Intraoperative diuresis
No 376 23 0.13
Donor type
Living donor 1151 52 0.84
DBD 373 14 0.23
DCD 386 22
Donor age (years) ≥60 664 40 0.04
Donor gender
Male (%) 930 42 0.85
Right kidney 677 27 0.54
Ischemic times in min
1st WIT 5.4  7.0 5.7  6.1 0.70
CIT >24 h 14 1 0.42
2nd WIT 31.1  13.8 26.1  11.0 0.001
Preoperative Hb 7.4  1.0 7.3  1.0 0.46
Preoperative platelets 228  85 226  75 0.94
Antithrombotic therapy
None 1287 46 0.26
Continued VKA* 38 15 <0.001
APT† 370 20 0.44
Intraoperative UFH 190 5 0.15
APT + intraoperative UFH 27 2 0.37
Postoperative heparin infusion 593 44 <0.001
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surgery. In the APT group, two patients received platelet
transfusion prior to surgery because clopidogrel was not
discontinued.
Thromboembolic and bleeding complications
After KTx, diagnoses of TEC were made based on clinical
symptoms or laboratory abnormalities and confirmed
with duplex imaging, renal scintigraphy or CT-scan.
DVT, extending to the popliteal vein or more proximally,
all cases of PE and thrombosis of the femoral artery, con-
firmed by radiological imaging ≤7 days after surgery,
were counted as events. Furthermore, all radiologically or
surgically confirmed cases of renal artery or renal vein
thrombosis ≤7 days post-transplantation were counted as
an event. Cases of postoperative bleeding ≤7 days were
extracted from follow-up documentation. Clinical symp-
toms suspected for bleeding, i.e., pain due to compres-
sion or conjunctival pallor, had to be accompanied by
either a sudden drop of hemoglobin, noticed by the treat-
ing physician, or compression on the graft as confirmed
on imaging. Bleeding requiring further intervention, by
blood transfusion, re-exploration or both, was then
counted as event.
Statistical methods and analyses
Descriptive statistics were presented as mean  standard
deviation (SD) or median with interquartile range (IQR)
for continuous variables and analyzed by student’s t-test,
ANOVA, Mann–Whitney U or Kruskal–Wallis test depend-
ing on distribution, evaluated by Shapiro Wilk-test. Cat-
egorical variables were presented as total with
percentages (n (%)). Differences between patients with
and without complications after transplantation were
evaluated by Chi-square and/or Fisher’s exact tests. Pri-
mary analyses focused on univariable regression analysis
to determine relationship between perioperative
antithrombotic therapy and incidence of TEC and bleed-
ing. Secondary analyses focused on multivariable regres-
sion analysis to adjust for potential confounders. Results
of the regression analyses were presented as odds ratio
(OR) with 95% confidence interval (CI) and its corre-
sponding P-value. Tests of significance are two-tailed
with significance set at P < 0.05. A P < 0.2 in univari-
able analysis and/or known risk factors from the litera-
ture were added to the adjusted multivariable model.
Hosmer–Lemeshow test was used to test fitness of the
model. The model was considered fit when P > 0.05.
Internal validation was performed using bootstrap sam-
pling with 1000 resamples. Discrimination of the model
was evaluated using Harrell’s C-index. Incidence of TEC
was analyzed as percent of patients experiencing TEC
≤7 days after transplantation. Time to TEC and time to
bleeding were calculated from day of transplantation
until day of diagnosis as described above. All statistical
analyses were performed using the Statistical Package for
the Social Sciences (SPSS v22; IBM Corp, Armonk, NY,
USA) and graphs were created using GRAPHPAD PRISM
v5.04 (GraphPad Software Inc.©, La Jolla, CA, USA).
Results
Baseline characteristics and pre- and intraoperative
parameters stratified for TEC and bleeding are shown in
Table 1 (TEC) and Table 2 (Bleeding). Mean age of the
total cohort was 54  14 years and 60% of patients
were male.
Table 2. Continued.
Baseline characteristics of KTx patients
Cases
P-valueCharacteristics No bleeding Bleeding ≤7 days
AB0 – blood group Incompatible 72 2 0.77
DGF 432 23 0.41
Shown are baseline characteristics in n (%). Ordinal variables are shown as median with interquartile range. Continuous vari-
ables are shown as mean  SD.
N, number in group; CAPD, continuous ambulatory peritoneal dialysis; ASA, American society for anaesthesiologists; BMI, body
mass index; eGFR, estimated glomerular filtration rate; CCI, Charlson Comorbidity Index; SLE, systemic lupus erythematosus;
DVT, deep venous thrombosis; DBD, donation after brain death; DCD, donation after circulatory death; WIT, warm ischemic
time; CIT, cold ischemic time; VKA, Vitamin K antagonists; APT, antiplatelet therapy; UFH: unfractionated heparin.
*Administration of VKA on day of transplantation, medication was continued and INR not corrected.
†Administration of APT was continued at the day of transplantation. Second WIT was defined as the time from cold storage
to recirculation (anastomosis time).
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Incidences of TEC
Twenty-one patients (n = 21/2000, 1.1%) developed
TEC ≤7 days after KTx. Fourteen (14/21, 67%) TEC
developed in patients who did not receive any form of
antithrombotic therapy and three (14%) in patients
treated with APT. The groups VKA and APT+UFH each
had one patient with an event of TEC (n = 1, 5%)
(Fig. 1). Two patients (11%) receiving UFH had an
event of TEC. Of all TEC, 19 were RGT, one case of
arterial thrombosis was found in the common femoral
artery (day 1) and in one case DVT occurred (day 7).
Incidence of TEC did not vary between the treatment
groups (P = 0.69). Median time for the development of
TEC was 1 day (1–3) (n = 13, 62%) (Fig. 2).
Risk factors for TEC
Univariable analysis (Table 3) shows that KTx with
multiple donor arteries increases the risk for the devel-
opment of TEC by 2.8-fold [odds ratio (OR) 2.79 (95%
CI: 1.15–6.79), P = 0.04]. For every recipient with a
BMI > 30 kg/m2, the added risk for developing TEC is
almost threefold [OR 2.85 (95% CI: 1.19–6.82),
P = 0.03]. Intraoperative diuresis was associated with
decreased risk of TEC [OR 0.27 (95% CI: 0.11–0.65),
P = 0.004]. A multivariable regression analysis could
not be performed without the risk of underfitting the
model owing to small numbers.
Incidences of postoperative bleeding
Postoperative bleeding occurred in 88 (4.4%) cases
≤7 days after transplantation. Fourty-six (52%) cases
occurred in the control group, 15 (17%) in the VKA
group, 20 (23%) in the APT group, five (6%) in the UFH
group and two (2%) in the APT + UFH group (Fig. 3).
Incidence of bleeding varied significantly between the
treatment groups (P = 0.006). Of all patients with postop-
erative bleeding, 47 required surgical intervention with or
without blood transfusion, and 17 required only a blood
transfusion. Median time for development of bleeding was
on the second postoperative day (1–4) (n = 45, 51%),
with a peak on the first day (n = 36, 41%) (Fig. 2).
Risk factors for bleeding ≤7 days after transplantation
In univariable analysis (Table 4), continued use of VKA
[OR 10.13 (95% CI: 5.33–19.52), P < 0.001] and post-
operative continuous heparin infusion increased the risk
[OR 2.22 (95% CI: 1.45–3.42), P < 0.001] for
postoperative bleeding. Donor age >60 years [OR 1.60
(95% CI: 1.04–2.46), P = 0.04] was associated with a
1.6-fold increased risk. Being of non-Caucasian ethnicity
increased the risk nearly twofold [OR 1.91 (95% CI:
1.13–3.24), P = 0.01] and patients suffering from CVD
had a 2.4-fold increased risk [OR 2.41 (95% CI: 1.55–
3.75), P < 0.001]. Furthermore, being pre-emptively
transplanted increased the risk by 1.7-fold [OR 1.70
(95% CI: 1.10–2.62), P = 0.02] and every point increase
on the American Society for Anaesthesiologists (ASA)-
scale by 2.1-fold [OR 2.10 (95% CI: 1.04–4.23),
P = 0.04]. A second warm ischemic time, defined as
time from cold storage to recirculation (anastomosis
time), >45 min [OR 0.46 (95% CI: 0.21–1.00),
P = 0.04] and smoking [OR 0.46 (95% CI: 0.23–0.93),
P = 0.03] reduced the risk of developing postoperative
bleeding by more than half. Every increase of 5 kg/m2
in recipient BMI decreased the risk by more than a
quarter [OR 0.72 (95% CI: 0.52–0.99) P = 0.05].
Multivariable regression analysis for postoperative
bleeding ≤7 days
For multivariable adjusted analyses, the following vari-
ables were entered in the model: UFH, VKA, APT, post-
operative heparin, non-Caucasian ethnicity of the
recipient, pre-emptive KTx, presence of CVD, BMI per
1 kg/m2 increase, donor age >60, intraoperative blood
loss >500 ml, CIT per hour increase, smoking, presence
of peripheral vascular disease (PVD) and diabetic
nephropathy (Table 5). Hosmer–Lemeshow test showed
fitness of the model (P = 0.98). The C-statistic of this
model is 0.75, indicating a high degree of discrimina-
tion. Pre-existing CVD [OR 2.01 (95% CI: 1.18–3.42),
P = 0.010], pre-emptive KTx [OR 2.23 (95% CI: 1.28–
3.89), P = 0.005], continued use of VKA [OR 6.60
(95% CI: 2.95–14.77), P < 0.001] and postoperative
heparin infusion [OR 1.69 (95% CI: 1.00–2.85),
P = 0.049] remained independently associated with risk
for postoperative bleeding ≤7 days after KTx. After
adjustment for VKA therapy, which is indicated in cer-
tain cardiovascular conditions and could thus be a con-
founding factor, CVD remained a significant risk factor
for bleeding [OR 2.46, (95% CI: 1.47–4.12), P = 0.001].
When patients with postoperative heparin infusion
(n = 637) were removed from the equation, pre-emp-
tive KTx remained associated with bleeding [OR 3.24
(95% CI: 1.42–7.41), P < 0.01]. Stratification for trans-
plant center did not show significant difference in
bleeding in the pre-emptively transplanted patients
(P = 0.23).
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Discussion
To our knowledge, we report on the largest series focus-
ing on postoperative thromboembolic and bleeding
complications after KTx. We identified a 1.1% incidence
of early TEC and 4.4% bleeding complications. This is
lower than reported in the literature [8–11,21,22]. High
BMI and multiple donor arteries were associated with
increased risk for TEC. Pre-emptive KTx, use of VKA,
CVD, and postoperative heparin infusion were indepen-
dent risk factors for early (re-)bleeding. Interestingly
intraoperative heparin, APT, or the combination were
not associated with an increased risk. TEC or bleeding
occurred mostly within the first days after KTx, with
the majority on the first postoperative day, which has
been reported before [21]. TEC in the first post-trans-
plant week, were predominantly RGT, whereas DVT
and PE were rare or absent. Because KTx recipients are
reported to have a sevenfold higher risk of venous
thromboembolism compared to the general population,
which confers an increased risk of graft loss and even
death [9,23], our results can help in identifying the
patients most at risk and provide a starting-point for
prospective studies in order to develop preventive
strategies. Since therapeutic options for RGT are scarce,
antithrombotic prophylaxis may decrease this risk.
While some data considering antithrombotic prophy-
laxis in KTx exist, these reports are limited by their










Figure 2 Number of TEC and
bleeding per day after
transplantation. n, number of group;
TEC, thromboembolic complication.
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sample size. Therefore, a clear answer as to whether
antithrombotic therapy increases bleeding risk had yet
to be found. Pawlicki et al. [22] reported an association
between increased risk for bleeding and antithrombotic
prophylaxis, but this study was limited by sample size
(n = 67), and suboptimal methodology: hematomas of
≥4 cm, with or without graft compression were scored
as bleeding events. In general, hematomas of ≥4 cm are
common after KTx and rarely have any clinical rele-
vance. Our inclusion criteria for bleeding were stricter,
and therefore the incidence of postoperative bleeding
was relatively low compared to other studies (4.9–
25.4%) [21,22]. The incidence is reported to decline to
0.2–1.9%, if only a reoperation is considered clinically
relevant [24]. Considered all above, our incidence seems
to be an accurate representation of clinically relevant
bleeding after KTx. High BMI was found to be associ-
ated with increased risk for TEC, while it reduced the
risk for bleeding. It is known that obesity leads to
hypercoagulability and several explanations for this
finding have been considered. Patients with higher BMI
could have more space for bleeding and would therefore
be less likely to develop bleeding with compression on
the graft or high body weight could possibly tamponade
the bleeding [21,25]. Difficulty in performing duplex
ultrasound on obese patients could lead to underreport-
ing of bleeding, although our inclusion criteria for
bleeding should have been able to identify these patients
as well. The higher volume of surrounding tissue could
also lead to impaired blood flow and thus increase the
risk for thrombosis by twofold. Contradictory results
have been reported regarding the increased risk for TEC
(especially renal artery thrombosis) in case of multiple
donor arteries [7,26,27] and this finding might therefore
be of less significance in a multivariable model. Another
study on bleeding risks after perioperative anticoagula-
tion concluded that the utilization of antithrombotic
prophylaxis does neither increase the incidence nor the
risk for bleeding in the perioperative period, except for
postoperative heparin infusion [28]. Heparin infusion,
starting within 24 h after surgery, has been associated
with an increased risk for bleeding before [29], as in
our analysis, whereas the prophylactic use of heparin
(5000 IU s.c. twice daily) is reported to be safe [30].
Others reported an increased risk of bleeding after con-
tinued VKA therapy as well, but concluded that the
indication for VKA therapy was nonmodifiable in cer-
tain patients [31]. We can concur this finding since all
patients on continued VKA therapy in our analysis had
a vital indication for anticoagulation therapy, i.e., due
to paroxysmal atrial fibrillation with high CHA2DS2-
VASc scores. In all cases, the treating physicians were
aware of the possible complications and deemed discon-
tinuing preoperatively as more threatening than the risk
of a postoperative bleeding. Aside from VKA therapy,
often indicated in certain cardiovascular diseases, CVD
was associated with an increased risk for bleeding, even
after correction for VKA or APT, most likely explained
Figure 3 Incidence (%) of bleeding
per treatment group. APT,
antiplatelet therapy; VKA, Vitamin K
antagonists; UFH, unfractionated
heparin (given intraoperatively).
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by the technical challenges of transplanting patients
with a high burden of CVD. A previous study men-
tioned that pre-emptive KTx is protective against
thrombosis [32]. Interestingly, we saw an increased risk
for bleeding in our pre-emptively transplanted cohort.
After adjusting for intraoperative heparin, predomi-
nantly given to pre-emptive patients in one center, pre-
emptive transplantation remained an independent risk
factor. To our knowledge, the general argument to
refrain from anticoagulation during KTx is often the
belief that patients on dialysis, in contrast to pre-emp-
tive patients, are considered hypocoagulable, because of
the residual effect of heparin used during dialysis and
the continuous activation of platelets through contact
with the dialysis membrane. However, uremic toxins,
which influence platelet function, develop in all patients
with renal failure and recent insights have shown that
dialysis could even lead to reduced risk of bleeding due
to removal of these uremic toxins [15,16]. Surgical
aspects, such as cross-clamping and anastomoses of ves-
sels, may also overcome the theoretically guarding
effects of uremia against thrombosis [8]. Therefore,
dialysis-dependent patients are at risk of both bleeding
and thrombotic complications. Recent analysis has
Table 3. Univariable analysis for possible risk factors for TEC.
Risk factors for Thromboembolic
complications (Univariable analysis
using Enter method of binary logistics.) Odds ratio (95% CI) P-value
AB0-incompatible 2.69 (0.61–11.81) 0.19
Preoperative VKA therapy
(not stopped, INR not corrected)
3.76 (0.49–29.04) 0.25
Preoperative antiplatelet therapy 0.68 (0.20–2.33) 0.78
Intraoperative heparin 0.46 (0.06–3.47) 0.71
Postoperative heparin infusion 0.67 (0.24–1.83) 0.43
Arteries >1 2.79 (1.15–6.79) 0.04
Blood loss >500 ml 2.05 (0.75–5.58) 0.23
CAPD (yes) 1.55 (0.56–4.25) 0.38
Coagulation disorder (yes) 0.99 (0.99–0.99) 1.00
Cold ischemic time per 1 h increase 1.08 (0.98–1.20) 0.14
DGF (yes) 0.56 (0.16–1.91) 0.44
Diabetic nephropathy (yes) 1.50 (0.50–4.48) 0.52
Donation of the right kidney 1.71 (0.68–4.33) 0.25
Donor age (<60 vs. >60) 2.04 (0.86–4.82) 0.10
Donor gender (female) 1.69 (0.71–3.99) 0.23
Donor (deceased) 1.67 (0.71–3.95) 0.24
Deceased donor type (DBD) 1.27 (0.38–4.19) 0.70
DVT medical history (yes) 1.34 (0.18– 10.15) 0.54
Ethnicity (non-white) 0.34 (0.05–2.55) 0.50
Intraoperative diuresis (yes) 0.27 (0.11–0.65) 0.004
Pre-emptive transplantation (yes) 1.12 (0.45–2.79) 0.81
Recipient age (≥ 50) 0.69 (0.29–1.65) 0.40
Recipient BMI (≥30) 2.85 (1.19–6.82) 0.03
Recipient gender (female) 1.69 (0.71–3.99) 0.23
SLE (yes) 3.76 (0.49–29.04) 0.25
Smoking (yes) 0.45 (0.10–1.94) 0.40
Time on dialysis (per 1 year increase) 0.89 (0.63–1.26) 0.51
Second warm ischemic time (≥ 45 min) 1.79 (0.65–4.97) 0.23
Recipient BMI per 5 kg/m2 increase 0.96 (0.50–1.84) 0.90
Charlson comorbidity index score per 1 point increase 0.86 (0.61–1.20) 0.37
ASA score per 1 point increase 1.17 (0.32–4.23) 0.81
Odds ratio is presented with 95% confidence interval (CI). An OR above 1.00 implies an increased risk compared to its equiva-
lent. An OR below 1.00 corresponds to a decreased risk. P-value <0.05 was considered statistically significant.
VKA, vitamin K antagonists; INR, international normalized ratio; CAPD, continuous ambulatory peritoneal dialysis; DGF, delayed
graft function; DBD, donation after brain death; DVT, deep venous thrombosis; BMI, body mass index; SLE, systemic lupus
erythematosus; ASA, American society of anaesthesiologists.
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shown that pre-emptively transplanted patients and
dialysis patients have a comparable ability for platelet
and coagulation activation prior to transplantation [17].
Therefore, differences might be found in platelet func-
tion, which could be worse in pre-emptive patients
compared to dialysis-dependent patients than previously
thought, since they do not benefit from the potentially
beneficial effect of hemodialysis on platelet dysfunction.
A few limitations of this study need to be addressed.
First, due low events numbers, multivariable analysis for
TEC was not feasible without leading to under fitting
the model and thus a detailed analysis of potential risk
factors is missing. Considering our incidence, a similar
multivariable analysis as performed for bleeding, would
require nearly 8000 KTx recipients. Second, because of
the retrospective study design and relatively low
incidence, potential confounding risk factors may have
been missed. A randomized study or propensity-
matched cohort would probably have given a more
robust outcome. However, given the many confounders
and low incidences, this requires many patients, making
a prospective study very challenging. Despite the skewed
distribution in our study, we present the largest series
with data from a real-world experience and provide reli-
able insights into risk factors for both TEC and bleeding
after KTx. Third, postoperative antithrombotic therapy
was not included in this study except for 5-day heparin
infusion. When preoperative anticoagulants were
stopped, reinitiation usually did not take place within
1–2 days after KTx, unless vital indications for anticoag-
ulation stated otherwise. Since most TEC or bleeding
occurred within the first postoperative day, we expect
Table 4. Univariable analysis for possible risk factors for postoperative bleeding.
Risk factors for bleeding (Univariable analysis using Enter method of binary logistics) Odds ratio (95% CI) P-value
AB0-incompatible 0.59 (0.14–2.45) 0.77
Preoperative VKA therapy (not stopped, INR not corrected) 10.13 (5.33–19.25) <0.001
Preoperative antiplatelet therapy 1.23 (0.74–2.04) 0.44
Intraoperative heparin 0.55 (0.22–1.36) 0.19
Postoperative heparin infusion 2.22 (1.45–3.42) <0.001
Arteries >1 1.35 (0.81–2.26) 0.24
Blood loss ≥ 500 ml 1.50 (0.90–2.49) 0.12
CAPD (yes) 0.70 (0.37–1.34) 0.28
Cold ischemic time per 1 h increase 1.06 (1.00–1.12) 0.05
DGF (yes) 1.23 (0.75–2.00) 0.41
Diabetic nephropathy (yes) 1.55 (0.90–2.67) 0.11
Donation of the right kidney 0.86 (0.53–1.38) 0.54
Donor age (≥ 60) 1.56 (1.02–2.40) 0.04
Donor gender (female) 1.11 (0.72–1.71) 0.63
Donor (deceased) 1.05 (0.68–1.62) 0.84
Deceased donor type (DBD) 0.66 (0.33–1.31) 0.23
Duration dialysis (per 1 year increase) 0.93 (0.80–1.08) 0.36
Ethnicity (non-white) 1.88 (1.11–3.18) 0.02
Intraoperative diuresis (yes) 0.68 (0.41–1.12) 0.13
Pre-emptive (yes) 1.66 (1.08–2.57) 0.02
Recipient gender (female) 1.11 (0.72–1.71) 0.63
Recipient age (>50) 1.18 (0.75–1.88) 0.48
Second warm ischemic time (≥45 min) 0.45 (0.21–0.98) 0.04
Smoking (yes) 0.46 (0.23–0.92) 0.02
Recipient BMI per 5 kg/m2 increase 0.73 (0.53–1.01) 0.05
Charlson comorbidity index score per 1 point increase 1.06 (0.93–1.21) 0.36
ASA score per 1 point increase 2.14 (1.06–4.31) 0.03
Cardiovascular disease 2.37 (1.53–3.67) <0.001
Peripheral vascular disease 1.65 (0.86–3.18) 0.13
Recipient BMI >30 kg/m2 0.52 (0.28–0.99) 0.04
Odds ratio with 95% confidence interval (CI). An OR above 1.00 implies an increased risk compared to its equivalent. An OR
below 1.00 corresponds to a decreased risk. P < 0.05 was considered statistically significant.
VKA, vitamin K antagonists; INR, international normalized ratio; CAPD, continuous ambulatory peritoneal dialysis; DGF, delayed
graft function; DBD, donation after brain death; BMI, body mass index; ASA, American society of anaesthesiologists.
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that this would not have significantly affected our
results. Furthermore, DVT and PE might have required
a longer follow-up until 30 days post-transplant, con-
sidered a reported cumulative risk [33]. In this study,
we aimed at analyzing early postoperative complications
in relation to perioperative antithrombotic prophylaxis.
Our results show that continued APT and intraopera-
tive heparin do not increase the incidence of bleeding
after KTx and that it is safe to use these agents in order to
prevent early postoperative TEC. We advise that VKA
should only be continued in patients with a vital indica-
tion for anticoagulation. Despite the significantly
increased risk, patients using VKA should not be
refrained from KTx, but instead should be monitored clo-
sely for early signs of postoperative bleeding, with i.e.,
daily duplex imaging in the first five postoperative days
and prophylactic placing of surgical drains seems advised.
Postoperative heparin infusion should be refrained from,
as several studies have now reported increased bleeding
risk with unclear advantages for prevention of TEC.
There is still a lot of uncertainty about the use of
antithrombotic prophylaxis during KTx. A cutoff point
based solely on dialysis dependence seems very arbitrary
and unfounded because pre-emptive patients also have a
poor kidney function, with the associated risks of an
impaired coagulation. Perhaps new criteria should be
established in which a high-risk group is defined who
would benefit most from antithrombotic prophylaxis
perioperatively. Given the dogmas that prevail, we hope
this study will add new insights and data into this long-
standing and recurrent problem. Further research is
needed to investigate the adjusted risk factors for early
TEC and the possible additional advantages of intraoper-
ative heparinization during KTx.
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Table 5. Multivariable regression analysis for risk factors for postoperative bleeding within 7 days after kidney
transplantation.
Risk factors for bleeding (Multivariable analysis using Enter method of binary logistics) Odds ratio (95% CI) P-value
Intraoperative heparin 1.22 (0.43–3.45) 0.711
Vitamin K antagonists 6.60 (2.95–14.77) <0.001
Postoperative heparin infusion 1.69 (1.00–2.85) 0.049
Antiplatelet therapy 1.51 (0.80–2.85) 0.204
Ethnicity of the recipient (non-Caucasian) 1.85 (0.98–3.49) 0.058
Pre-emptive transplantation 2.23 (1.28–3.89) 0.005
BMI per 1 kg/m2 increase 0.93 (0.87–0.98) 0.011
Donor age >60 1.63 (0.99–2.69) 0.054
Intraoperative blood loss >500 ml 1.60 (0.91–2.83) 0.103
Cold ischemic time per 1 h increase 1.02 (0.97–1.06) 0.450
Smoking at time of transplantation 0.39 (0.17–0.89) 0.025
Cardiovascular disease 2.01 (1.18–3.42) 0.010
Peripheral vascular disease 1.36 (0.62–3.01) 0.446
Diabetic nephropathy 0.86 (0.42–1.76) 0.680
Odds ratio with 95% confidence interval. All factors adjusted for risk factors in the table. P < 0.05 was considered statistically
significant.
CI, confidence interval; BMI, body mass index.
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